Abstract

Similar oral preparations of isosorbide mononitrate have recently been marketed by four unrelated companies. This is unusual but understandable for an unpatentable drug of promise. Like other nitrates this drug has anti-anginal and haemodynamic effects of value in the treatment of ischaemic heart disease and heart failure. The manufacturers claim that its 100% bioavailability should make it more effective, longer acting and more acceptable than slow-release isosorbide dinitrate (ISDN).